Development and validation of the high-throughput, fully-automated NeuMoDx assay for HPV detection

Labs like yours play a critical role in screening for HPV to help prevent and treat cervical cancer. The NeuMoDx system can expand your lab’s capabilities with automated, high-throughput HPV testing and true random access for accurate and timely results. This complements the WHO global strategy to eliminate cervical cancer, which proposes 70% of women be screened with a high-performance test by 2030.

In this live webinar on International HPV Awareness Day, Dr. Hesselink will discuss the current landscape of HPV assays for cervical cancer screening, as well as analytical and clinical performance and validation. Mr. Ong will provide details about the NeuMoDx technology.

Join us to learn how to:
•   Detect HPV in a high-throughput setting
•   Accelerate cervical cancer screening with a fully automated HPV assay
•   Improve your workflow with NeuMoDx

About the speaker

Bart Hesselink, PhD, Senior Scientific Officer of Self-screen B.V.

Bart is Senior Scientific Officer of Self-screen B.V. and certified epidemiologist. In 2008 he received his PhD degree on defining HPV test requirements for cervical cancer screening. He has a demonstrated history in valorization of fundamental research into molecular clinical diagnostic assays. Together with key opinion leader Prof. Peter Snijders he developed multiple CE/IVD certified technologies targeting biomarkers that enable full molecular cervical cancer screening. He has a long track record and expertise in clinical validation of key HPV assays and is (co)author of over 40 peer reviewed papers.